| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $5.0M | -5.3% |
| Cost of Revenue | $3.0M | -10.2% |
| R&D Expense | $53K | -96.2% |
| SG&A Expense | $9.6M | -33.5% |
| Operating Income | -$3.6M | +73.8% |
| Pre-tax Income | -$4.3M | +67.2% |
| Income Tax | $8K | +0.0% |
| Net Income | -$7.0M | +49.7% |
| EPS (Basic) | -$5.17 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $4.2M | -34.9% |
| Short-term Investments | $0 | -100.0% |
| Accounts Receivable | $1.2M | +128.6% |
| Inventory | $904K | -53.8% |
| Current Assets | $9.2M | -38.3% |
| Total Assets | $13.5M | -31.4% |
| Current Liabilities | $2.6M | -28.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$9.6M | +37.1% |
| Capital Expenditures | $16K | +220.0% |
| Investing Cash Flow | $7.3M | +269.0% |
| Financing Cash Flow | $9K | -99.8% |
| Free Cash Flow | -$9.6M | +37.0% |
| +54.2% |
| EPS (Diluted) | -$5.17 | +54.2% |
| Total Liabilities |
| $7.3M |
| +4.2% |
| Stockholders' Equity | $6.2M | -51.5% |